Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer

By  

Oncology, Vol. 71, Iss. 1-2, 2007-04 ,pp. : 40-48

Karger

Access to resources Recommend Favorite

Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials

By  

Oncology, Vol. 83, Iss. 5, 2012-08 ,pp. : 241-247

Karger

Access to resources Recommend Favorite

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna   Maschio Michael   Leahy Kevin J.   Yunger Simon   Easaw Jacob C.   Weinstein Milton C.  

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of Colorectal Cancer Screening

By Lansdorp-Vogelaar Iris   Knudsen Amy B.   Brenner Hermann  

Epidemiologic Reviews, Vol. 33, Iss. 1, 2011-05 ,pp. : 88-100

Oxford University Press

Access to resources Recommend Favorite

The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 224-230

Karger

Access to resources Recommend Favorite